MAM
VIR icon

Martingale Asset Management’s Vir Biotechnology VIR Stock Holding History

Martingale Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,802
Closed -$401K – 891
2026
Q1 		$401K Hold
44,802
– – 0.01% 689
2025
Q4 		$270K Sell
44,802
-2,212
-5% -$13.2K 0.01% 708
2025
Q3 		$268K Hold
47,014
– – 0.01% 710
2025
Q2 		$237K Hold
47,014
– – 0.01% 738
2025
Q1 		$305K Hold
47,014
– – 0.01% 678
2024
Q4 		$345K Sell
47,014
-12
-0% -$95 0.01% 666
2024
Q3 		$352K Buy
47,026
+104
+0.2% +$903 0.01% 687
2024
Q2 		$418K Buy
46,922
+898
+2% +$8.61K 0.01% 638
2024
Q1 		$466K Sell
46,024
-19
-0% -$194 0.01% 631
2023
Q4 		$463K Buy
46,043
+9,834
+27% +$89.9K 0.01% 630
2023
Q3 		$339K Buy
36,209
+10,122
+39% +$144K 0.01% 669
2023
Q2 		$640K Buy
26,087
+912
+4% +$22.9K 0.01% 560
2023
Q1 		$586K Buy
25,175
+8,208
+48% +$210K 0.01% 581
2022
Q4 		$429K Buy
16,967
+6,401
+61% +$157K 0.01% 650
2022
Q3 		$204K Buy
+10,566
New +$269K ﹤0.01% 780
2021
Q1 		– Sell
-9,523
Closed -$256K – 924
2020
Q4 		$256K Buy
+9,523
New +$310K ﹤0.01% 780

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Martingale Asset Management's VIR Position: Q2 2026 in Review

Martingale Asset Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 44,802 shares — an estimated $401K sold.

Martingale Asset Management first reported a position in VIR in Q4 2020 and held it in 16 quarters. The position peaked at $640K in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Martingale Asset Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Martingale Asset Management sold 44,802 Vir Biotechnology shares in Q2 2026, an estimated $401K.
  • Martingale Asset Management first reported a position in Vir Biotechnology in Q4 2020 and held it in 16 quarters.
  • Martingale Asset Management's Vir Biotechnology position peaked at $640K in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.